Key Points
- Kestra Medical Technologies insider Brian Daniel Webster sold 51,900 shares for approximately $1.27 million at an average price of $24.52. The sale was made to cover tax withholding tied to vested equity awards, leaving him with 475,215 shares.
- KMTS recently reported weaker-than-expected quarterly results, with an EPS loss of $0.67 versus the $0.59 consensus estimate, revenue of $28.64 million, and negative net margins and return on equity.
- The stock was up 0.8% at $25.27, while analysts maintained a consensus “Hold” rating and an average price target of $27.83; price targets ranged from $17 to $32.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Traci Umberger sold 3,580 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.04, for a total value of $86,063.20. Following the sale, the insider directly owned 195,825 shares in the company, valued at $4,707,633. This trade represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kestra Medical Technologies Stock Up 0.8%
Shares of Kestra Medical Technologies stock opened at $25.27 on Friday. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -10.44 and a beta of 0.58. The company's 50 day moving average is $22.86 and its 200 day moving average is $22.54. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million for the quarter. Research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.
Hedge Funds Weigh In On Kestra Medical Technologies
A number of large investors have recently added to or reduced their stakes in KMTS. Farther Finance Advisors LLC acquired a new stake in Kestra Medical Technologies in the fourth quarter valued at approximately $31,000. Russell Investments Group Ltd. increased its holdings in shares of Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after acquiring an additional 474 shares in the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Kestra Medical Technologies in the 4th quarter valued at approximately $72,000. BNP Paribas Financial Markets raised its holdings in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock worth $65,000 after buying an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company's stock worth $74,000 after acquiring an additional 656 shares during the period.
Analyst Ratings Changes
Several brokerages have commented on KMTS. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Weiss Ratings lowered shares of Kestra Medical Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, July 16th. The Goldman Sachs Group cut their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a "neutral" rating on the stock in a research note on Thursday, April 9th. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Finally, Oppenheimer started coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a "market perform" rating for the company. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies presently has an average rating of "Hold" and an average price target of $27.83.
View Our Latest Stock Report on Kestra Medical Technologies
Kestra Medical Technologies Company Profile
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
